Hubei Biocause Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Hubei Biocause Pharmaceutical has a total shareholder equity of CN¥33.6B and total debt of CN¥23.8B, which brings its debt-to-equity ratio to 70.9%. Its total assets and total liabilities are CN¥282.4B and CN¥248.8B respectively.
Key information
70.9%
Debt to equity ratio
CN¥23.79b
Debt
Interest coverage ratio | n/a |
Cash | CN¥23.45b |
Equity | CN¥33.55b |
Total liabilities | CN¥248.82b |
Total assets | CN¥282.37b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 000627's short term assets (CN¥43.5B) exceed its short term liabilities (CN¥23.5B).
Long Term Liabilities: 000627's short term assets (CN¥43.5B) do not cover its long term liabilities (CN¥225.3B).
Debt to Equity History and Analysis
Debt Level: 000627's net debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: 000627's debt to equity ratio has increased from 9.9% to 70.9% over the past 5 years.
Debt Coverage: 000627's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 000627's interest payments on its debt are well covered by EBIT.